4823 T3D4768 Flutamide An antiandrogen with about the same potency as cyproterone in rodent and canine species. 13311-84-7 3397 C11H11F3N2O3 White powder. 111.5-112.5°C 9.45 mg/L Rapidly and completely absorbed. Flutamide is a nonsteroidal antiandrogen that blocks the action of both endogenous and exogenous testosterone by binding to the androgen receptor. In addition Flutamide is a potent inhibitor of testosterone-stimulated prostatic DNA synthesis. Moreover, it is capable of inhibiting prostatic nuclear uptake of androgen. Flutamide is rapidly and extensively metabolized, with flutamide comprising only 2.5% of plasma radioactivity 1 hour after administration. Route of Elimination: Flutamide and its metabolites are excreted mainly in the urine with only 4.2% of a single dose excreted in the feces over 72 hours. Half Life: The plasma half-life for the alpha-hydroxylated metabolite of flutamide (an active metabolite) is approximately 6 hours. No indication of carcinogenicity to humans (not listed by IARC). For the management of locally confined Stage B2-C and Stage D2 metastatic carcinoma of the prostate In animal studies with flutamide alone, signs of overdose included hypoactivity, piloerection, slow respiration, ataxia, and/or lacrimation, anorexia, tranquilization, emesis, and methemoglobinemia. 2014-09-11T05:15:47Z 2014-12-24T20:26:57Z Flutamide C07653 5132 DB00499 true CC(C)C(O)=NC1=CC(=C(C=C1)N(=O)=O)C(F)(F)F C11H11F3N2O3 InChI=1S/C11H11F3N2O3/c1-6(2)10(17)15-7-3-4-9(16(18)19)8(5-7)11(12,13)14/h3-6H,1-2H3,(H,15,17) InChIKey=MKXKFYHWDHIYRV-UHFFFAOYSA-N 276.2118 276.072176843 Exogenous Solid 3.35 HMDB14642 CHEMBL806 3280 <p>Jack Lawrence James, Louis Frank Molnar, Jr., Tania E. Toney-Parker, &#8220;Processes for preparing flutamide compounds and compounds prepared by such processes.&#8221; U.S. Patent US 6,228,401, issued November, 1976.</p>